In the face of challenging times for TCR-T therapy development, our conference serves as a crucial forum for researchers, clinicians, and industry leaders. Through dialogue, knowledge-sharing, and collaboration, we aim to provide essential support and drive progress in the field, helping to navigate through difficulties and advance towards groundbreaking therapies.

The recent submission of a Biologics License Application (BLA) by Adaptimmune is a remarkable milestone, signifying remarkable progress in gaining regulatory approval for their TCR-based cancer therapy. This achievement indicates a pivotal step forward, paving the way for broader accessibility of this innovative treatment to patients in critical need.

The 5th TCR-based Therapies for Solid Tumors Summit returned as the only TCR conference where TCR pipelines have the centre stage, serving as your ultimate platform to network with the most senior industry leaders in biopharma dedicated to accelerating clinical and commercial development of TCR-based therapeutics.